Blog
RSS FeedPosted by Michael Wonder on 18 Nov 2019
Ontario and Quebec provide reimbursement for HIV therapies Pifeltro (doravirine) and Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate)
18 November 2019 - For more than 30 years, Merck has been committed to scientific research and discovery in HIV that ...
Posted by Michael Wonder on 18 Nov 2019
Biosimilars make progress in the Canadian market, but stakeholders see more work ahead
18 November 2019 - While much attention over the past few weeks has been on the US biosimilars market, with its ...
Posted by Michael Wonder on 18 Nov 2019
Picturing ELSI+: a visual representation of ethical, legal, and social issues, and patient experiences in health technology assessment in Canada
15 November 2019 - Consideration of ethical, legal, and social issues plus patient values (ELSI+) in health technology assessment is challenging ...
Posted by Michael Wonder on 18 Nov 2019
'This drug saved my life;' cystic fibrosis patient accuses drug company, Canada of stalling on approval
17 November 2019 - A West Island woman living with cystic fibrosis says the prohibitive price of a drug is ...
Posted by Michael Wonder on 29 Oct 2019
Costly prescription eye treatment highlights a loophole in Canada’s drug-price regulation process
28 October 2019 - The Ontario government has begun covering $100,000-a-year eye drops for an ultrarare disease, bringing relief to ...
Posted by Michael Wonder on 28 Oct 2019
It’s time for Canada to embrace universal pharmacare and protect drug coverage from corporate erosion
28 October 2019 - President Trump recently unveiled an executive order — originally titled “Protecting Medicare from Socialist Destruction” — ...
Posted by Michael Wonder on 23 Oct 2019
Canadian election clears path for universal drug plan
23 October 2019 - Canada’s Liberal government is more likely to pass a universal prescription drug plan after losing its majority ...
Posted by Michael Wonder on 23 Oct 2019
Patients in Quebec now have access to Dupixent for the treatment of moderate-to-severe atopic dermatitis
22 October 2019 - Quebec becomes the first province to list Dupixent for public reimbursement in adult patients. ...
Posted by Michael Wonder on 22 Oct 2019
Which health care promises will the Liberals realistically be able to keep?
22 October 2019 - The Liberals have a number of significant health care-related campaign promises to live up to as ...
Posted by Michael Wonder on 21 Oct 2019
Voters beware: national pharmacare is unnecessary, bad for privately insured Canadians and costly for taxpayers
18 October 2019 - Research has shown it would be less disruptive and less expensive to just fill the gaps caused ...
Posted by Michael Wonder on 16 Oct 2019
Election 2019: unprecedented hope for universal pharmacare
15 October 2019 - Pharmacare continues to be the most salient unfinished business of Canada’s public health care system since Medicare ...
Posted by Michael Wonder on 09 Oct 2019
Low-income Canadians struggling to pay for medications plead for pharmacare
8 October 2019 - Three of the major federal parties have promised they’ll introduce universal pharmacare if elected. ...
Posted by Michael Wonder on 03 Oct 2019
What you need to know about pharmacare this election
3 October 2019 - We’ve had reports, election promises, advisory councils and investigations over the years, all examining the question ...
Posted by Michael Wonder on 03 Oct 2019
Dr. Brian O’Rourke to retire as CADTH’s President and CEO
3 October 2019 - Dr. Brian O’Rourke has announced his intention to retire from CADTH, effective 31 March 2020. ...
Posted by Michael Wonder on 24 Sep 2019
9 in 10 Canadians want national pharmacare: Heart & Stroke poll
24 September 2019 - Canadians overwhelmingly support a national pharmacare program, according to a new poll commissioned by Heart & ...